BioInsights - Leveraging lessons from the COVID-19 pandemic to accelerate the development and production of viral-based gene therapies

Leveraging lessons from the COVID-19 pandemic to accelerate the development and production of viral-based gene therapies

Cell & Gene Therapy Insights 2021; 7(8), 1159

10.18609/cgti.2021.155

Published: 5 October 2021
FastFacts
Yasser Kehail

Watch the video or read the poster to learn about:

  • Optimizing plasmid transfection-based production of AAV in suspension culture using single-use bioreactors
  • Implementing scalable and robust technologies for efficient purification of biologically active AAV.
  • Scalable technologies and Enterprise solutions for advancing viral vector manufacturing

Yasser Kehail has over 12 years of experience in cell culture manufacturing, development, and optimization. He currently supports clients working on different therapeutic modalities, such as monoclonal antibodies, plasmid DNA, vaccines, and viral vectors, consulting specifically on upstream scale-up strategies and technology transfer. Yasser began his career in cell culture manufacturing at Biogen. He then moved to Upstream PD at Amgen before joining Cytiva, formerly part of GE Healthcare’s Life Sciences business, in 2014.